Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31019026 | 1.00 | MEN1 (0.43) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL28466920 | 1.00 | MEN1 (0.43) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL6012032 | 0.88 | MEN1 (0.53) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL3052925 | 0.88 | MEN1 (0.53) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL3052928 | 0.88 | MEN1 (0.53) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL5152168 | 0.87 | NPC1 (0.47) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL5152176 | 0.87 | NPC1 (0.47) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL19897161 | 0.86 | RIPK1 (0.48) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL31306998 | 0.86 | RIPK1 (0.48) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL19897159 | 0.86 | RIPK1 (0.48) | MEN1KMT2ALMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034156-A1 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| EP-4467198-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS AND PRODRUGS THEREOF USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| EP-3759113-B1 | 10-(DI(PHENYL)METHYL)-4-HYDROXY-8,9,9A,10-TETRAHYDRO-7H-PYRROLO[1',2':4,5]PYRAZINO[1,2-B]PYRIDAZINE-3,5-DIONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE ORTHOMYXOVIRUS REPLICATION FOR TREATING INFLUENZA | NOVARTIS AG (CH) | 2024-09-11 | — | — | EP | disclosed |
| US-12071441-B2 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | NOVARTIS AG (CH) | 2024-08-27 | — | — | US | disclosed |
| US-20230322793-A1 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322793-A1 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322793-A1 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-11629149-B2 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | NOVARTIS AG (CH) | 2023-04-18 | — | — | US | disclosed |
| US-20200407366-A1 | 10-(DI(PHENYL)METHYL)-4-HYDROXY-8,9,9A,10-TETRAHYDRO-7H-PYRROLO[1 ',2':4,5]PYRAZINO[1,2-B]PYRIDAZINE-3,5-DIONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE ORTHOMYXOVIRUS REPLICATION FOR TREATING INFLUENZA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071441-B2 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | MAVS, ZC3HAV1, EIF2AK2 | MEN1 4346/4885KMT2A 1248/4885LMNA 2057/4885 |
| US-20200407366-A1 | 10-(DI(PHENYL)METHYL)-4-HYDROXY-8,9,9A,10-TETRAHYDRO-7H-PYRROLO[1 ',2':4,5]PYRAZINO[1,2-B]PYRIDAZINE-3,5-DIONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE ORTHOMYXOVIRUS REPLICATION FOR TREATING INFLUENZA | MAVS, ZC3HAV1, EIF2AK2 | MEN1 4314/4885KMT2A 1290/4885LMNA 2139/4885 |
| US-11629149-B2 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | MAVS, ZC3HAV1, EIF2AK2 | MEN1 4346/4885KMT2A 1248/4885LMNA 2057/4885 |
| US-20250034156-A1 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza | MAVS, ZC3HAV1, EIF2AK2 | MEN1 4314/4885KMT2A 1290/4885LMNA 2139/4885 |
| US-20230322793-A1 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza | MAVS, ZC3HAV1, EIF2AK2 | MEN1 4314/4885KMT2A 1290/4885LMNA 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.